A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

Abstract Background Inflammatory cytokine markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-lymphocyte ratio, and platelet-to-lymphocyte ratio, play important roles as prognostic markers in several solid malignancies, including prostate cancer. We previously reported the NLR as a...

Full description

Bibliographic Details
Main Authors: Takashi Kawahara, Masashi Kato, Kenichi Tabata, Ippei Kojima, Hiroshi Yamada, Osamu Kamihira, Hideyasu Tsumura, Masatsugu Iwamura, Hiroji Uemura, Yasuhide Miyoshi
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Cancer
Subjects:
The NLR
Abiraterone acetate
Enzalutamide
Online Access:http://link.springer.com/article/10.1186/s12885-020-07410-2

Internet

http://link.springer.com/article/10.1186/s12885-020-07410-2

Similar Items